Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Lenvatinib in High-Grade Serous Ovarian Cancer
NCT05114421Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2021
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab and lenvatinib in High-Grade Serous Ovarian Carcinoma (HGSOC), primary peritoneal cancer (PPC) and fallopian tube carcinoma (PFTC) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Change in the proportion of CD8+ and CD4+ cells that are PD1+CD38+ at 1 year and Change in the proportion of CD8+ and CD4+ cells that are Ki67+ at 1 year. Started Nov 2021; status: active, not recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
High-Grade Serous Ovarian Carcinoma (HGSOC)primary peritoneal cancer (PPC)fallopian tube carcinoma (PFTC)
Beyond the preview
Go deeper on NCT05114421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05114421.